KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Retained Earnings: 2013-2025

Historic Retained Earnings for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to -$1.1 billion.

  • Xenon Pharmaceuticals' Retained Earnings fell 36.74% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 36.74%. This contributed to the annual value of -$899.5 million for FY2024, which is 35.23% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Retained Earnings stood at -$1.1 billion, which was down 8.66% from -$1.0 billion recorded in Q2 2025.
  • Xenon Pharmaceuticals' Retained Earnings' 5-year high stood at -$294.3 million during Q1 2021, with a 5-year trough of -$1.1 billion in Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$771.0 million (2024), whereas its average is -$795.7 million.
  • Data for Xenon Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 40.11% (in 2023) over the last 5 years.
  • Xenon Pharmaceuticals' Retained Earnings (Quarterly) stood at -$357.4 million in 2021, then crashed by 35.08% to -$482.7 million in 2022, then crashed by 37.78% to -$665.1 million in 2023, then plummeted by 35.23% to -$899.5 million in 2024, then tumbled by 36.74% to -$1.1 billion in 2025.
  • Its Retained Earnings stands at -$1.1 billion for Q3 2025, versus -$1.0 billion for Q2 2025 and -$964.5 million for Q1 2025.